How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,634 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. A case of multiple squamous cell carcinomas arising from red tattoo pigment Full Text available with Trip Pro

A case of multiple squamous cell carcinomas arising from red tattoo pigment Ornamental tattooing involves the administration of exogenous pigments into the skin to create a permanent design. Our case focuses on a 62-year-old woman who presented with an inflamed enlarging nodule on her right proximal calf, which arose within the red pigment of an ornamental tattoo. The nodule was diagnosed as squamous cell carcinoma (SCC) and subsequently excised. Over the course of the following year (...) , the patient was diagnosed with a total of five additional SCCs that also arose within the red pigment of the tattoo. The increased popularity of tattooing and the lack of industry safety standards for tattoo ink production, especially metal-laden red pigments, may lead to more cases of skin cancer arising within tattoos among patients of all ages.

2017 International journal of women's dermatology

102. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck

). It inhibits the proliferation of cells that depend on EGFR activation for growth. Mark Marketing eting authorisation authorisation Cetuximab has a UK marketing authorisation 'for the treatment of patients with squamous cell cancer of the head and neck… in combination with platinum-based chemotherapy for recurrent and/or metastatic disease' . Adv Adverse erse reactions reactions Very common adverse reactions with cetuximab include skin reactions, which occur in more than 80% of patients, and low blood (...) with platinum-based chemotherapy followed by cetuximab as maintenance therapy until disease progression. The initial loading dose is 400 mg/m 2 body surface area (BSA) given at a rate not exceeding 5 mg/minute. Subsequent weekly maintenance doses are 250 mg/m 2 BSA each. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

103. Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborat (Abstract)

Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborat Advancements in solid organ transplantation successfully extend the lives of thousands of patients annually. The tenet of organ stewardship aims to prevent the futile expenditure of scarce donor organs in patient populations with high (...) for transplant candidates with a history of either cutaneous squamous cell carcinoma, malignant melanoma, or Merkel cell carcinoma. © Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons.

2016 American Journal of Transplantation

104. Pemetrexed disodium - Carcinoma, Non-Small-Cell Lung, Mesothelioma

lung cancer other than predominantly squamous cell histology (see section 5.1). Pemetrexed Krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1). Pemetrexed Krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non (...) for Pemetrexed Krka is: Malignant pleural mesothelioma Pemetrexed Krka in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancer Pemetrexed Krka in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed Krka is indicated as monotherapy

2018 European Medicines Agency - EPARs

105. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. (Abstract)

Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. Vismodegib is a first-in-class agent targeting the hedgehog signaling pathway for treatment of patients with locally advanced basal cell carcinoma (BCC) and metastatic BCC. There have been concerns about the development of squamous cell carcinoma (SCC) in patients treated with this drug.We sought to determine whether treatment with vismodegib is associated with an increase in the risk of cutaneous (...) SCC.In this retrospective cohort study, patients treated with vismodegib as part of phase I and II clinical studies were compared with participants from the University of California, San Francisco, Nonmelanoma Skin Cancer Cohort who received standard therapy for primary BCC. In total, 1675 patients were included in the analysis, and the development of SCC after vismodegib exposure was assessed.The use of vismodegib was not associated with an increased risk of subsequent development of SCC (adjusted

2017 Journal of American Academy of Dermatology

106. Genetic association between TNF-α promoter polymorphism and susceptibility to squamous cell carcinoma, basal cell carcinoma, and melanoma: A meta-analysis. Full Text available with Trip Pro

Genetic association between TNF-α promoter polymorphism and susceptibility to squamous cell carcinoma, basal cell carcinoma, and melanoma: A meta-analysis. Tumor necrosis factor-alpha (TNF-α) is a multifunctional pro-inflammatory cytokine that plays an important role in cancer development. We performed a meta-analysis to assess the relationship between single nucleotide polymorphisms in the TNF-α promoter region (rs1800629 and rs361525) and susceptibility to squamous cell carcinoma (SCC (...) ), basal cell carcinoma (BCC) and melanoma. After database retrieval, article selection, data extraction, and quality assessment, 20 articles comprising 4865 cases and 6329 controls were included in this study. rs1800629 was associated with an increased overall risk of SCC, lung SCC, and oral SCC in the AA vs G and AA vs GG+GA genetic models (all OR>1, Passociation <0.05). No increased risk of skin SCC, skin BCC or melanoma was observed (all Passociation >0.05). Rs361525 was not associated with overall

2017 Oncotarget

107. Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope

-regulated Device Product: No Keywords provided by Sung Hyun Pyun, Speclipse Australia Pty Ltd: skin cancer laser spectroscopy non-invasive diagnostics Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Carcinoma, Basal Cell Skin Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Neoplasms, Basal Cell Neoplasms by Site Skin Diseases (...) is irradiated, the emission spectra of tissue is automatically generated from the spectrometer inside the device and simultaneously displayed on the monitor, and stored in the laptop. The spectral data stored in the laptop is wirelessly accessible using Google drive. An algorithm then determines whether the skin is from a normal, pigmented normal, benign, squamous cell carcinoma (SCC), basal cell carcinoma (BCC) or melanoma based on the spectral 'signature'. These algorithms have been determined during

2017 Clinical Trials

108. Cigarette smoking and the risks of basal cell carcinoma and squamous cell carcinoma. Full Text available with Trip Pro

Cigarette smoking and the risks of basal cell carcinoma and squamous cell carcinoma. Sunlight is the principal environmental risk factor for keratinocyte cancers, but other carcinogens have also been implicated, including tobacco smoke. Findings have been conflicting, however. We investigated associations between cigarette smoking and incidence of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) in QSkin, a prospective study of skin cancer (N = 43,794). Smoking history was self (...) -reported at baseline; newly diagnosed BCCs and SCCs were ascertained through data linkage and verified by histopathology reports. We restricted analyses to white participants who at baseline reported no past history of skin cancer excisions and no more than five destructively treated actinic skin lesions. We fitted Cox proportional hazards models, adjusted for known confounders. Compared with never smokers, current smokers had significantly lower risks of BCC (hazard ratio = 0.6; 95% confidence

2017 Journal of Investigative Dermatology

109. Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010. Full Text available with Trip Pro

Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010. To determine population-based incidence estimates of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).We reviewed the medical records of a population-based cohort diagnosed with nonmelanoma skin cancer between January 2, 2000, and December 31, 2010. The age- and sex-adjusted incidence rates were calculated and compared (...) , 310.3-332.2) and that of cSCC from 61.8 (95% CI, 52.3-71.4) to 162.5 (95% CI, 154.6-170.3). Over time, the anatomical distribution of BCC shifted from the head and neck to the torso and that of cSCC shifted from the head and neck to the extremities.The incidences of BCC and cSCC are increasing, with a disproportionate increase in cSCC relative to BCC. There is also a disproportionate increase in the incidence of both tumors in women, as well as a shift of anatomical distributions.Copyright © 2017

2017 Mayo Clinic Proceedings

110. Linear Malignant Melanoma In Situ: Reports and Review of Cutaneous Malignancies Presenting as Linear Skin Cancer Full Text available with Trip Pro

in this report. A medical literature search engine, PubMed, was used to search the following terms: cancer, cutaneous, in situ, linear, malignant, malignant melanoma, melanoma in situ, neoplasm, and skin. The 25 papers that were generated by the search and their references, were reviewed; 10 papers were selected for inclusion. The cancer of the skin typically presents as round lesions. However, basal cell carcinoma and squamous cell carcinoma may arise from primary skin conditions or benign skin neoplasms (...) such as linear epidermal nevus and linear porokeratosis. In addition, linear tumors such as basal cell carcinoma can occur. The development of linear cutaneous neoplasms may occur secondary to skin tension line or embryonal growth patterns (as reflected by the lines of Langer and lines of Blaschko) or exogenous factors such as prior radiation therapy. Cutaneous neoplasms and specifically melanoma in situ can be added to the list of linear skin lesions.

2017 Cureus

111. Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin. Full Text available with Trip Pro

* are fundamentally different from those associated with 999del5. We report for the first time an association between K3326* and small cell lung cancer (odds ratio [OR] = 2.06, 95% confidence interval [CI] = 1.35 to 3.16) and squamous cell carcinoma of the skin (OR = 1.69, 95% CI = 1.26 to 2.26). Individuals homozygous for K3326* reach old age and have children. Unlike BRCA2 999del5, the K3326* allele does not affect the level of BRCA2 transcripts, and the allele is expressed to the same extent as the wild-type (...) Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin. Most pathogenic mutations in the BRCA2 gene carry a high risk of hereditary breast and ovarian cancer (HBOC). However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer. The Icelandic population provides an opportunity for comprehensive characterization of the cancer risk profiles

2018 Journal of the National Cancer Institute

112. Timing of Subsequent New Tumors in Patients Who Present With Basal Cell Carcinoma or Cutaneous Squamous Cell Carcinoma. Full Text available with Trip Pro

Timing of Subsequent New Tumors in Patients Who Present With Basal Cell Carcinoma or Cutaneous Squamous Cell Carcinoma. Patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) (often termed nonmelanoma skin cancer or keratinocyte carcinoma [KC]) often develop new KCs, but information is limited on the frequency and timing of these subsequent tumors. This information is crucial to guide follow-up care.To determine the timing of subsequent new KCs in patients who (...) are related to biological or behavioral differences or to differences in health care services should be investigated further to inform and improve care. Ongoing routine screening for subsequent KC may not be indicated for all patients with KC. Skin cancer screening can be improved with a better understanding of the course and frequency of subsequent KC diagnoses.

2015 JAMA dermatology (Chicago, Ill.)

113. miR-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival Full Text available with Trip Pro

miR-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival Previously, we identified miR-125b as a key regulator of the undifferentiated state of hair follicle stem cells. Here, we show that in both mice and humans, miR-125b is abundantly expressed, particularly at early stages of malignant progression to squamous cell carcinoma (SCC), the second most prevalent cancer worldwide. Moreover, when elevated in normal murine (...) epidermis, miR-125b promotes tumor initiation and contributes to malignant progression. We further show that miR-125b can confer "oncomiR addiction" in early stage malignant progenitors by delaying their differentiation and favoring an SCC cancer stem cell (CSC)-like transcriptional program. To understand how, we systematically identified and validated miR125b targets that are specifically associated with tumors that are dependent on miR-125b. Through molecular and genetic analysis of these targets, we

2014 Genes & development

114. Validation of the English Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire. (Abstract)

was a prospective, observational study. Patients with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) were asked to fill out BaSQoL, Skin Cancer Index (SCI), and Hospital Anxiety and Depression Scale (HADS) questionnaires. Descriptive statistics and classical test theory were used to assess validity.One hundred eighty-seven subjects enrolled in this study: 122 with BCC and 65 with SCC. One hundred seventy-one subjects (91.4%) completed questionnaires at all 3 time points; 16 patients (8.6%) were (...) Validation of the English Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire. Keratinocyte carcinomas (KC) impact patient quality of life (QoL). There is a need for validated QoL instruments specific to KC. The Basal and Squamous Cell Carcinoma QoL (BaSQoL) questionnaire was developed to comprehensively measure issues of importance to patients with KC.To validate and characterize the BaSQoL questionnaire for QoL measurement after diagnosis and treatment of KC.This

2019 Dermatologic Surgery

115. Characteristics of Patients Hospitalized for Cutaneous Squamous Cell Carcinoma. (Abstract)

Characteristics of Patients Hospitalized for Cutaneous Squamous Cell Carcinoma. Knowledge regarding the inpatient burden of cutaneous squamous cell carcinoma (cSCC) is limited.To provide nationally representative estimates for hospitalization characteristics due to cSCC and determine predictors for increased length of stay (LOS) and cost of care.A retrospective cohort study of the 2009 to 2015 National Inpatient Sample. Weighted multivariate logistic/linear regression models were created (...) to evaluate sociodemographic factors associated with cSCC hospitalization and to assess characteristics associated with cost of care and LOS.This study included 15,784 cSCC and 255,244,626 non-SCC inpatients (prevalence = 6.2/100,000 inpatients). On average, cSCC hospitalizations lasted 5.8 days and cost $66,841.00. Cutaneous squamous cell carcinoma most often occurred on the scalp (30.57%), face (21.08%), and lower limb (11.93%). Controlling for all other factors, cSCC inpatients presented to larger

2019 Dermatologic Surgery

116. Somatic mutations in kinetochore gene KNSTRN are associated with basal proliferating actinic keratoses and cutaneous squamous cell carcinoma. (Abstract)

Somatic mutations in kinetochore gene KNSTRN are associated with basal proliferating actinic keratoses and cutaneous squamous cell carcinoma. Mutations in kinetochore gene KNSTRN accelerate the development of cutaneous squamous cell carcinoma (SCC) and may correlate with different histological classifications of actinic keratosis (AKs).To determine KNSTRN gene mutation frequency in healthy skin (HS), actinically damaged skin (ADS), in AKs with different histomorphological gradings, and invasive

2019 Journal of the European Academy of Dermatology and Venereology

117. Expression of indolamine-2,3-dioxygenase and cyclooxygenase-2 in different disease stages of cutaneous squamous cell carcinoma. (Abstract)

Expression of indolamine-2,3-dioxygenase and cyclooxygenase-2 in different disease stages of cutaneous squamous cell carcinoma. 31251418 2019 07 09 1468-3083 2019 Jun 28 Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Expression of indolamine-2,3-dioxygenase and cyclooxygenase-2 in different disease stages of cutaneous squamous cell carcinoma. 10.1111/jdv.15763 Gambichler T T https://orcid.org/0000-0001-7862-3695 Department of Dermatology (...) , Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany. Selke L L Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany. Rüddel I I Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany. Dreißigacker M M Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany. Stockfleth E E Department of Dermatology, Skin Cancer Center, Ruhr-University Bochum, Bochum, Germany. Schmitz L L https://orcid.org/0000

2019 Journal of the European Academy of Dermatology and Venereology

118. Data independent acquisition proteomic analysis can discriminate between actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma. Full Text available with Trip Pro

Data independent acquisition proteomic analysis can discriminate between actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma. Actinic keratosis (AK), Bowen's disease (BD) and cutaneous squamous cell carcinoma (cSCC) are heterogeneous keratinocytic skin lesions (KSL). Biomarkers that can accurately stratify these lesion types are needed to support a new paradigm of personalised, precise management of skin neoplasia. In this paper, we used the data independent acquisition (...) (DIA) proteomics workflow, SWATH-MS, to analyse formalin-fixed paraffin embedded (FFPE) samples of normal skin and KSL including well differentiated (WD), moderately differentiated (MD) and poorly differentiated (PD) cSCC. We quantified 3574 proteins across 93 samples studied. Differential abundance analysis identified 19, five and six protein markers exclusive to AK, BD and cSCC lesions, respectively. Among cSCC lesions of various levels of tumour differentiation, 118, 230 and 17 proteins showed

2019 Journal of Investigative Dermatology

119. Immunotherapeutic Strategies for Cutaneous Squamous Cell Carcinoma Prevention in Xeroderma Pigmentosum. (Abstract)

Immunotherapeutic Strategies for Cutaneous Squamous Cell Carcinoma Prevention in Xeroderma Pigmentosum. Xeroderma pigmentosum (XP) is an autosomal recessive disorder of nucleotide excision repair, characterized by hypersensitivity to ultraviolet light (UV) radiation.1-3 In individuals with XP, the incidence of non-melanoma skin cancers prior to the age of 20 years is approximately 10,000 times that seen in the general population.4 The most common cause of death in this patient population (...) is skin cancer, including metastatic melanoma and metastatic cutaneous squamous cell carcinoma (cSCC).4 Sun avoidance is the main mode of skin cancer prevention in XP patients.5 However, the development of invasive skin cancers at an early age and challenges associated with avoiding sun exposure highlight the critical need for additional cancer prevention strategies in this high-risk population. We report cSCC incidence before and after starting immune checkpoint blockade (ICB) therapy in a single

2019 British Journal of Dermatology

120. The detection rate of Human Papillomavirus (HPV) in well differentiated squamous cell carcinoma and keratoacanthoma: is there new evidence for a viral pathogenesis of keratoacanthoma? (Abstract)

The detection rate of Human Papillomavirus (HPV) in well differentiated squamous cell carcinoma and keratoacanthoma: is there new evidence for a viral pathogenesis of keratoacanthoma? The "keratinocyte skin cancer" term stands as a sort of umbrella covering different stages within the progression of cutaneous squamous cell carcinoma (cSCC). The invasive forms of are further classified on the basis of histopathologic differentiation grade as well differentiated, moderate and poorly (...) differentiated cSCC. Whether or not keratoacanthoma (KA) represents a form of well differentiated tumor remains currently a matter of debate. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>